A New Assay for Monitoring Functional Serum Anti-Tumour Necrosis Factor Antibody Level in Crohn's Disease Patients Who Maintained and Those Who Lost Response to Anti-TNF

Monitoring functional serum antitumor ne

Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF

✍ Akihiro Yamada; Koji Sono; Nobuo Hosoe; Nobuo Takada; Yasuo Suzuki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

Background: Infliximab (IFX) is an antitumor necrosis factor (TNF)-a antibody used to treat Crohn's disease (CD). However, antibodies to IFX (ATI) emerge, which can impair its efficacy. A fluid-phase enzyme immunoassay (FP-EIA) was established for measuring serum functional IFX (f-IFX) in CD patient